

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal (STA)

#### Cangrelor for preventing atherothrombotic events in people undergoing percutaneous coronary intervention or surgery

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• The Medicines Company (cangrelor)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• Anticoagulation Europe</li> <li>• Arrhythmia Alliance</li> <li>• Atrial Fibrillation Association</li> <li>• Black Health Agency</li> <li>• Blood Pressure UK</li> <li>• British Cardiac Patients Association</li> <li>• Coronary Prevention Group</li> <li>• Cardiomyopathy Association</li> <li>• Different Strokes</li> <li>• Equalities National Council</li> <li>• Heart Care Partnership (UK)</li> <li>• HEART UK</li> <li>• Lifeblood: The Thrombosis Charity</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Network of Sikh Organisations</li> <li>• Pumping Marvellous</li> <li>• The Somerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Specialist Association</li> <li>• Association of Anaesthetists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Nursing in Cardiovascular Care</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (clopidogrel)</li> <li>• Aspire Pharma (clopidogrel)</li> <li>• Arrow Generics (clopidogrel)</li> <li>• AstraZeneca (ticagrelor)</li> <li>• Baxter Healthcare (unfractionated heparin)</li> <li>• Beacon Pharmaceuticals (clopidogrel)</li> <li>• <u>Bristol-Myers Squibb (clopidogrel)</u></li> <li>• Consilient Health (clopidogrel)</li> <li>• Correvio UK (tirofiban [glycoprotein IIb/IIIa inhibitor])</li> <li>• Daiichi Sankyo (prasugrel)</li> </ul>

## Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Association of Stroke Physicians</li> <li>• British Atherosclerosis Society</li> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis</li> <li>• British Society for Heart Failure</li> <li>• British Thoracic Society</li> <li>• British Vein Institute</li> <li>• Clinical Leaders of Thrombosis (CLOT)</li> <li>• College of Emergency Medicine</li>   <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science &amp; Technology</li> <li>• Society for Vascular Technology</li> <li>• Society of Vascular Nurses</li> <li>• UK Health Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li>   <li><u>Others</u></li> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Redbridge CCG</li> <li>• NHS Sutton CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Dexcel-Pharma (clopidogrel)</li> <li>• Dr Reddy's Laboratories (clopidogrel)</li> <li>• GlaxoSmithKline (eptifibatide [glycoprotein IIb/IIIa inhibitor])</li> <li>• Lilly UK (prasugrel, abciximab [glycoprotein IIb/IIIa inhibitor])</li> <li>• Leo Laboratories (tinzaparin [low molecular weight heparin], unfractionated heparin)</li> <li>• Mylan UK (clopidogrel)</li> <li>• Pfizer (dalteparin [low molecular weight heparin])</li> <li>• Sandoz (clopidogrel)</li> <li>• Sanofi (clopidogrel, enoxaparin [low molecular weight heparin])</li> <li>• Teva UK (clopidogrel)</li> <li>• Wockhardt UK (clopidogrel, unfractionated heparin)</li>   <li><u>Relevant research groups</u></li> <li>• Antithrombotic Trialists Collaboration</li> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Peripheral Vascular Diseases Group</li> <li>• Cochrane Stroke Group</li> <li>• CODA</li> <li>• European Council for Cardiovascular Research</li> <li>• Health Research Authority</li> <li>• MRC Clinical Trials Unit</li> <li>• National Heart Research Fund</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li>   <li><u>Evidence Review Group</u></li> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul>

## Appendix C

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="818 342 1238 376"><u>Associated Guideline Groups</u></p> <ul data-bbox="818 383 1342 416" style="list-style-type: none"><li data-bbox="818 383 1342 416">• National Clinical Guideline Centre</li></ul> <p data-bbox="818 456 1294 490"><u>Associated Public Health Groups</u></p> <ul data-bbox="818 497 1310 566" style="list-style-type: none"><li data-bbox="818 497 1174 530">• Public Health England</li><li data-bbox="818 535 1310 566">• Public Health Wales NHS Trust</li></ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.